MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance

Scientists investigated the roles of IRF4 and MYC in this context. Using bone marrow aspirates from patients with immunomodulatory drugs naïve or refractory multiple myeloma, they examined IKZF1/3 protein levels and IRF4/MYC gene expression following ex vivo pomalidomide treatment via flow cytometry and qPCR.
[Clinical Cancer Research]